<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418884</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10098</org_study_id>
    <nct_id>NCT02418884</nct_id>
  </id_info>
  <brief_title>The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus</brief_title>
  <official_title>The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Run Run Shaw Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to validate the hypothesis that the treatment of rosuvastatin could
      increase the score of Calcification of Coronary artery(CAC) density in coronary artery
      disease(CAD) patients with diabetes mellitus.CAD patients with diabetes who confirmed CAC
      will receive rosuvastatin (20mg/d) therapy for 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcification of atherosclerotic plaque is a complicated and organic active process, which is
      one of the main pathologic features of atherosclerosis. Widely coverage of CAC is correlated
      with the greater likelihood of coronary events.With the increasing density of CAC, the risk
      of cardiovascular disease (CVD) declines.Some studies showed that the calcified plaque in
      stable CHD is denser.

      Statins are widely used in the treatment of atherosclerotic cardiovascular disease. Treatment
      of statins may increase the density score of CAC, thus, promote the unstable atherosclerotic
      plaque to the stable plaque.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Density Score of Coronary Artery Calcification in CAD patients with Diabetes Mellitus</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the level of serum sclerostin in CAD patients with diabetes mellitus</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the volume score of CAC in CAD patients with diabetes mellitus</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CAD+DM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Using self controlled study to validate the hypothesis that the treatment of rosuvastatin could increase the score of CAC density in CAD patients with diabetes mellitus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.</description>
    <arm_group_label>CAD+DM</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures

          2. Male and female adults aged 18-70 years old

          3. CHD patients without stent implantation determined by coronary angiography or coronary
             CT examination;

          4. Combined with type 2 diabetes: HbA1c≥6.5%, FPG≥7.0mmol/L, 2h blood glucose≥11.1mmol/L

          5. Patients who confirmed CAC(Agatston score ≥50,measured by 64 row spiral CT6)

        Exclusion Criteria:

          1. CHD Patients plan to recieve coronary stenting implantation or coronary artery bypass
             grafting;

          2. Patients combined with severe pulmonary, liver and kidney dysfunction

          3. Classed as III-IV grade of New York Heart Association functional

          4. Pregnancy test was positive，lactation woman and in women of child-bearing potential
             not using appropriate contraceptive measures.

          5. Life expectancy within 24 months or less

          6. Patients combined valvular heart disease and cardiomyopathy

          7. Patients combined cancer

          8. Patients with atrial fibrillation

          9. Patients who is allergic to statins

         10. Patients with myopathy

         11. Patients with active liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guosheng Fu, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Run Run Shaw Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guosheng Fu, MD/PhD</last_name>
    <email>maoyihui_007@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenbin Zhang</last_name>
    <email>dream_flash_mx@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes : an intravascular ultrasound study. Circulation. 2000 Feb 15;101(6):598-603.</citation>
    <PMID>10673250</PMID>
  </reference>
  <reference>
    <citation>Leber AW, Knez A, White CW, Becker A, von Ziegler F, Muehling O, Becker C, Reiser M, Steinbeck G, Boekstegers P. Composition of coronary atherosclerotic plaques in patients with acute myocardial infarction and stable angina pectoris determined by contrast-enhanced multislice computed tomography. Am J Cardiol. 2003 Mar 15;91(6):714-8.</citation>
    <PMID>12633805</PMID>
  </reference>
  <reference>
    <citation>Shemesh J, Apter S, Itzchak Y, Motro M. Coronary calcification compared in patients with acute versus in those with chronic coronary events by using dual-sector spiral CT. Radiology. 2003 Feb;226(2):483-8.</citation>
    <PMID>12563143</PMID>
  </reference>
  <reference>
    <citation>Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, Nakamura Y, Yamashita H, Yamagishi H, Takeuchi K, Naruko T, Haze K, Becker AE, Yoshikawa J, Ueda M. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004 Nov 30;110(22):3424-9. Epub 2004 Nov 22.</citation>
    <PMID>15557374</PMID>
  </reference>
  <reference>
    <citation>Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, Boon NA, Newby DE; Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart. 2006 Sep;92(9):1207-12. Epub 2006 Jan 31.</citation>
    <PMID>16449511</PMID>
  </reference>
  <reference>
    <citation>Terry JG, Carr JJ, Kouba EO, Davis DH, Menon L, Bender K, Chandler ET, Morgan T, Crouse JR 3rd. Effect of simvastatin (80 mg) on coronary and abdominal aortic arterial calcium (from the coronary artery calcification treatment with zocor [CATZ] study). Am J Cardiol. 2007 Jun 15;99(12):1714-7. Epub 2007 Apr 26.</citation>
    <PMID>17560880</PMID>
  </reference>
  <reference>
    <citation>Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, Carr JJ, Budoff MJ, Allison MA. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014 Jan 15;311(3):271-8. doi: 10.1001/jama.2013.282535. Erratum in: JAMA. 2015 Apr 7;313(13):1374.</citation>
    <PMID>24247483</PMID>
  </reference>
  <reference>
    <citation>Koos R, Brandenburg V, Mahnken AH, Schneider R, Dohmen G, Autschbach R, Marx N, Kramann R. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis. 2013 May;22(3):317-25.</citation>
    <PMID>24151757</PMID>
  </reference>
  <reference>
    <citation>Brandenburg VM, Kramann R, Koos R, Krüger T, Schurgers L, Mühlenbruch G, Hübner S, Gladziwa U, Drechsler C, Ketteler M. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol. 2013 Oct 10;14:219. doi: 10.1186/1471-2369-14-219.</citation>
    <PMID>24112318</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Run Run Shaw Hospital</investigator_affiliation>
    <investigator_full_name>Guo Sheng Fu</investigator_full_name>
    <investigator_title>MD/PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

